Evidence map›Paper›PMID 36747920›Full record

ArticleHeliyon2023

FIMICS: A panel of long noncoding RNAs for cardiovascular conditions.

Huseyin Firat, Lu Zhang, Shounak Baksi, Przemyslaw Leszek, Eric Schordan, Samir Ounzain, Jan Kottwitz, Dimitri Patriki, Bettina Heidecker, Thomas F Lüscher and 3 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Prediction of COVID-19 severity using machine learning.Clinical and translational medicine · 2024
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

Huseyin FiratFiralis SA, Huningue, France.
Lu ZhangCardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg.
Shounak BaksiCardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg.
Przemyslaw LeszekThe Heart Failure and Transplantology Department, Institute of Cardiology, Warsaw, Poland.
Eric SchordanFiralis SA, Huningue, France.
Samir OunzainHAYA Therapeutics, Lausanne, Vaud, Switzerland.
Jan KottwitzDivision of Anesthesiology, Intensive Care, Rescue and Pain Medicine, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland.
Dimitri PatrikiDepartment of Cardiology, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Bettina HeideckerCharité Universitätsmedizin Berlin, Germany.
Thomas F LüscherRoyal Brompton & Harefield Hospitals GSTT, Imperial College and Kings College London, U.K. and Center for Molecular Cardiology, University of Zurich, Switzerland.
Thierry PedrazziniExperimental Cardiology Unit, Department of Cardiovascular Medicine, University of Lausanne Medical School, Lausanne, Switzerland.
Yvan DevauxCardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg.
EU-CardioRNA COST Action (CA17129)
Luxembourg Institute of Health · LUFiralis (France) · FRCharité - Universitätsmedizin Berlin · DEHarefield Hospital · GBInstitute of Cardiology · PLKantonsspital St. Gallen · CHUniversity Hospital of Zurich · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disorders such as heart failure are leading causes of mortality. Patient stratification via identification of novel biomarkers could improve management of cardiovascular diseases of complex etiologies. Long-noncoding RNAs (lncRNAs) are highly tissue-specific in nature and have emerged as important biomarkers in human diseases. In this study, we aimed to identify cardiac-enriched lncRNAs as potential biomarkers for cardiovascular conditions. Deep RNA sequencing and quantitative PCR identified differentially expressed lncRNAs between failing and non-failing hearts. An independent dataset was used to evaluate the enrichment of lncRNAs in normal hearts. We identified a panel of 2906 lncRNAs, named FIMICS, that were either cardiac-enriched or differentially expressed between failing and non-failing hearts. Expression of lncRNAs in blood samples differentiated patients with myocarditis and acute myocardial infarction. We hereby present the FIMICS panel, a readily available tool to provide insights into cardiovascular pathologies and which could be helpful for diagnosis, monitoring and prognosis purposes.

Indexed as

BiomarkerCardiac enriched RNACardiovascular conditionDeep RNA sequencingHeart failureLong-noncoding RNA

Identifiers

PMID36747920
PMCPMC9898641
OpenAlexW4319332793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.